Amgen Prepares for Key Insights at the 2026 Leerink Partners Global Healthcare Conference

Amgen Gears Up for the Leerink Partners Global Healthcare Conference

Amgen, a prominent player in the biotechnology realm, prepares to showcase its latest advancements at the forthcoming Leerink Partners 2026 Global Healthcare Conference on March 11, 2026. The event is significant not just for its caliber but also for the insights it promises. Peter Griffith, Amgen's executive vice president and chief financial officer, alongside Jasper van Grunsven, senior vice president of rare disease, will lead a fireside chat, providing a platform to discuss the company’s pioneering efforts in medicine development. This presentation is poised to strengthen Amgen's commitment to transparency and accessibility, as it will be streamed live for a diverse audience that includes the media, investors, and the general public.

Amgen's legacy of over 45 years underscores its dedication to innovating solutions for serious health challenges. The company's scientific endeavors are evident through its focus on biological and technological breakthroughs that aim to enhance patient care globally. As it seeks to expand its influence in treating an array of conditions—from cancer to rare diseases—Amgen remains steadfast in its mission to improve lives through effective treatments. The upcoming presentation is an opportunity for the company to highlight ongoing projects and new drug developments, particularly emphasizing its commitment to addressing underserved areas in healthcare.

The significance of this conference extends beyond merely presenting data; it is a forum where Amgen can engage with stakeholders, share its vision, and reinforce its standing as a front-runner in biotechnology. The company continually earns recognition for its innovation and workplace culture, having received accolades from reputable publications like Fast Company and Forbes. Being listed among the distinguished companies on the Dow Jones Industrial Average® and the Nasdaq-100 Index® demonstrates Amgen's vital role in not only the biotech industry but also the broader healthcare community.

In addition to the conference details, Amgen encourages its stakeholders to access further information through its official website, where viewers can find archived webcasts and additional resources for up to 90 days post-event. For media queries, Elissa Snook is the contact point, while Casey Capparelli addresses investor relations needs. The event marks a pivotal moment for Amgen as it continues to define its legacy in developing groundbreaking therapies.